On-demand treatment that helps you fight back
Actor portrayal.
For US Residents Only
Actor portrayal.
INBRIJA, the on-demand inhaled levodopa,
may start to work in as little as 10 minutes
For people taking carbidopa/levodopa for Parkinson's disease (PD) and experiencing
the return of symptoms between regular doses of medication, adding INBRIJA can help.
In a large clinical trial, INBRIJA started improving motor symptoms in as early as 10 minutes
and significant relief in motor symptoms was seen in 30 minutes of taking INBRIJA.
Rescue the moments in your day with INBRIJA
INBRIJA is an inhaled form of the levodopa in your regular carbidopa/levodopa PD medication. INBRIJA does not replace your regular carbidopa/levodopa medicine.
You can use INBRIJA as needed* to fight Parkinson's symptoms when they return.
*1 dose (2 capsules) per OFF
period up to 5 times per day.
Selected Important Safety Information
Tell your healthcare provider if you take:
- MAO-B inhibitors
- dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
- isoniazid
- iron salts or multivitamins that contain iron salts
Please see below for additional Important Safety Information.
INBRIJA can help you manage the return of your symptoms
INBRIJA is used in addition to your usual Parkinson's medications. It may start to work in as
little as 10 minutes. In a large study, significant relief in motor symptoms was seen in
30 minutes of taking INBRIJA.
INBRIJA is orally inhaled.
- INBRIJA is inhaled levodopa, so it goes through your lungs and is absorbed faster than oral
carbidopa/levodopa- Before using INBRIJA, tell your healthcare provider if you have asthma, chronic obstructive
pulmonary disease (COPD), or any chronic lung disease - Tell your healthcare provider if you experience bronchospasm. People with asthma, COPD,
or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this
occurs, stop taking INBRIJA and seek immediate medical attention
- Before using INBRIJA, tell your healthcare provider if you have asthma, chronic obstructive
- INBRIJA is inhaled levodopa, so it goes through your lungs and is absorbed faster than oral carbidopa/levodopa
- Before using INBRIJA, tell your healthcare provider if you have asthma, chronic obstructive
pulmonary disease (COPD), or any chronic lung disease - Tell your healthcare provider if you experience bronchospasm. People with asthma, COPD,
or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this
occurs, stop taking INBRIJA and seek immediate medical attention
- Before using INBRIJA, tell your healthcare provider if you have asthma, chronic obstructive
- INBRIJA is used in addition to your regular carbidopa/levodopa (CD/LD) medication. INBRIJA
does not replace your regular CD/LD medicines. Use it when your regular PD medications
aren't working as expected and your symptoms return - Going through the lungs means that absorption of the medicine is not affected by meals or
other conditions in your gut
INBRIJA is for use as needed
Take it as prescribed when your symptoms return (OFF periods). Use 1 dose (2 capsules) per OFF period and no more than 5 doses (10 capsules) per day.
INBRIJA is lightweight and portable
INBRIJA is easy to carry with you. Store your INBRIJA at room temperature 68°F to 77°F (20 °C to 25 °C) in a dry place.
Keep the capsules in their foil (blister) packages until just before you're ready to use them.
Selected Important Safety Information
Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.
Tell your healthcare provider if you experience the following side effects:
- falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
- withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
- low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
- hallucinations and other psychosis – INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
- unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
- uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson’s medicines may need to be changed.
- bronchospasm – people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
- increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
- changes in certain lab values including liver tests
Please see below for additional Important Safety Information.
Talk to your doctor about a $0 initial co-pay† for INBRIJA
†Limitations and restrictions apply.Indication
INBRIJA is a prescription medicine used when needed for OFF episodes in adults with Parkinson's treated with regular carbidopa/levodopa medicine. INBRIJA does not replace regular carbidopa/levodopa medicine.
Important Safety Information
Do not use INBRIJA if you take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last 2 weeks.
Before using INBRIJA, tell your healthcare provider about your medical conditions, including:
- asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease
- daytime sleepiness, sleep disorders, sleepiness/drowsiness without warning, or use of medicine that increases sleepiness, including antidepressants or antipsychotics
- dizziness, nausea, sweating, or fainting when standing up
- abnormal movement (dyskinesia)
- mental health problems such as hallucinations or psychosis
- uncontrollable urges like gambling, sexual urges, spending money, or binge eating
- glaucoma
- pregnancy or plans to become pregnant. It is unknown if INBRIJA will harm an unborn baby.
- breastfeeding or plans to breastfeed. Levodopa can pass into breastmilk and it is unknown if it can harm the baby.
Tell your healthcare provider if you take:
- MAO-B inhibitors
- dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
- isoniazid
- iron salts or multivitamins that contain iron salts
Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.
Tell your healthcare provider if you experience the following side effects:
- falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
- withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
- low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
- hallucinations and other psychosis - INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
- unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
- uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson's medicines may need to be changed.
- bronchospasm - people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
- increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
- changes in certain lab values including liver tests
The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.
Do not orally inhale more than 1 dose (2 capsules) for any OFF period. Do not take more than 5 doses (10 capsules) in a day.
Please see the Patient Information Leaflet.
INBRIJA® Indication
Treats OFF periods in adults taking carbidopa/levodopa (CD/LD). INBRIJA doesn't replace CD/LD.
Important Safety Information
Don't use if you have taken a nonselective monoamine oxidase inhibitor (eg, phenelzine, tranylcypromine) within the last 2 weeks.
SEE MORE 